Skip to main content

About GEP-NETs

Important Safety Information


  • Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer...


LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut...

References: 1. National Center for Advancing Translational Sciences. Neuroendocrine tumor. Accessed April 8, 2021. 2. National Cancer Institute. Neuroendocrine tumor. Accessed April 8, 2021. 3. American Society of Clinical Oncology. Neuroendocrine Tumors: Introduction. Accessed June 23, 2021. 4. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335-1342. 5. US Food and Drug Administration. Rare Diseases at FDA. Accessed June 23, 2021. 6. Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629-5638. 7. Sackstein PE, O’Neil DS, Neuget AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45(4):249-258. 8. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794-1803. 9. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 10. Campana D, Tomassetti P. Incidence, epidemiology, aetiology and staging, classification, clinical presentation/signs and symptoms, diagnosis, staging procedures/investigation. In: PET/CT in Neuroendocrine Tumors, Clinicians’ Guides to Radionuclide Hybrid Imaging. 1st ed. Springer International; 2016:1-5. 11. Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017;3(1):43-53. 12. Vinik AI, Woltering EA, Warner RRP, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39(6):713-734.